ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Malonic and Methylmalonic Aciduria (CMAMMA): Gene Identification and Outcome Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01289158
Recruitment Status : Unknown
Verified October 2010 by McGill University Health Center.
Recruitment status was:  Recruiting
First Posted : February 3, 2011
Last Update Posted : February 8, 2011
Sponsor:
Information provided by:
McGill University Health Center

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The investigators are interested in learning more about the changes found in the condition called "Combined elevation of Malonic and MethylMalonic Acid, or CMAMMA. " Malonic, or MA and MethylMalonic, or MMA, are acids formed from the breakdown of protein under normal conditions. However, in the condition called CMAMMA there is an increase of these acids in the blood and urine, which is not normal.

Some people with high MA and MMA in their blood and urine have a serious disease, starting as a baby or young child that includes heart disease and problems in learning. These people have changes in a special enzyme called Malonyl CoA Decarboxylase (MCD). Other people who have a high level of MA and MMA do not have any obvious illness. The investigators are not sure why they have high levels of MA and MMA and why they are not sick.

The goal of this study is to learn more about why some people have a high level of MA and MMA and to make sure there are no medical problems as a result of these high levels. The investigators also want to find out which gene and enzyme cause the high levels of MA and MMA.


Condition or disease
Malonic Aciduria Methylmalonic Acidemia

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 6 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Study Start Date : February 2011
Estimated Primary Completion Date : February 2012
Estimated Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
non-classical CMAMMA, classical CMAMMA


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Biospecimen Retention:   Samples With DNA
  1. A 5 cc sample of blood from a vein in EDTA tube for DNA testing
  2. A 5 cc sample of urine sample to measure the levels of MA and MMA
  3. An additional 5 cc (1 tsp) of blood sample will be collected from the parents for DNA testing

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Biochemical Genetics clinics patients with non-classical CMAMMA
Criteria

Inclusion Criteria:

  1. Elevated Malonic and Methylmalonic Acid in blood and urine
  2. Any age
  3. Any sex
  4. Asymptomatic

Exclusion Criteria:

  1. Defect in malonyl-coenzyme A decarboxylase (MCD) enzyme
  2. History of metabolic acidosis, developmental delay and seizures
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01289158


Contacts
Contact: Ahmed Alfares, M.B.B.S 5144124427 ahmed.alfares@mail.mcgill.ca

Locations
Canada, Quebec
McGill University Health Center Recruiting
Montreal, Quebec, Canada, H3H1P3
Contact: Ahmed Alfares, M.B.B.S    5144124427    ahmed.alfares@mail.mcgill.ca   
Principal Investigator: Nancy Braverman         
Sub-Investigator: Ahmed Alfares         
Sponsors and Collaborators
McGill University Health Center
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
The Research Institute of the McGill University Health Centre  This link exits the ClinicalTrials.gov site

Responsible Party: Dr. Nancy Braverman, The Research Institute of the MUHC | McGill University Health Centre
ClinicalTrials.gov Identifier: NCT01289158     History of Changes
Other Study ID Numbers: 10-131-PED
First Posted: February 3, 2011    Key Record Dates
Last Update Posted: February 8, 2011
Last Verified: October 2010

Keywords provided by McGill University Health Center:
malonic and methylmalonic aciduria
malonyl-coenzyme A decarboxylase
MLYCD